Mobocertinib: A Lifeline at Risk

Mobocertinib, the sole TKI licensed in the UK for EGFR+ Exon 20 patients, faces withdrawal this March. We at EGFR+ UK are advocating against this decision until a viable alternative is available.

We're taking our case to the House of Lords on Feb 14, seeking to overturn this decision. The debate will be televised, marking a pivotal moment for patients across the UK.

What This Means for You:

New patients will be able to access this drug until it’s withdrawn in March, but not after this date. If you are currently taking Mobocertinib (or if you are prescribed it between now and the time of withdrawal), you will still be able to access this drug after the withdrawal date… you just need to talk to your oncology team, and ask them to sign you up to Takeda’s compassionate use programme.